Aplicación de la proteómica y biología de sistemas al estudio del matrisoma y miRNAs en las Distrofias Musculares Congénitas

PI16/00579

Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Estatal de I+D+I Orientada a los Retos de la Sociedad
Subprograma Salud, cambio demográfico y bienestar
Convocatoria Proyectos de investigación en salud (Modalidad Proyectos de investigación en salud) (AE Salud 2016)
Año convocatoria 2016
Unidad de gestión Instituto de Salud Carlos III (ISCIII)
Centro beneficiario FUNDACIÓ PER A LA RECERCA I LA DOCENCIA SANT JOAN DE DÉU (FSJD) / FUNDACIÓN PARA LA INVESTIGACIÓN Y LA DOCENCIA SANT JOAN DE DÉU (FSJD)
Centro realización HOSPITAL SAN JUAN DE DIOS ESPLUGUES
Identificador persistente http://dx.doi.org/10.13039/501100003329

Publicaciones

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Proteomic and functional characterisation of extracellular vesicles from collagen VI deficient human fibroblasts reveals a role in cell motility

Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
  • Badosa, Carmen
  • Roldán, Mónica
  • Fernández Irigoyen, Joaquín
  • Santamaría Martínez, Enrique
  • Jiménez-Mallebrera, Cecilia
Extracellular vesicles (EVs) are key mediators of cell-to-cell communication. Their content reflects the state of diseased cells representing a window into disease progression. Collagen-VI Related Muscular Dystrophy (COL6-RD) is a multi-systemic disease involving different cell types. The role of EVs in this disease has not been explored. We compared by quantitative proteomics the protein cargo of EVs released from fibroblasts from patients with COL6-RD and controls. Isolated EVs contained a significant proportion of the most frequently reported proteins in EVs according to Exocarta and Vesiclepedia. We identified 67 differentially abundant proteins associated with vesicle transport and exocytosis, actin remodelling and the cytoskeleton, hemostasis and oxidative stress. Treatment of control fibroblasts with EVs from either patient or healthy fibroblasts altered significantly the motility of cells on a cell migration assay highlighting the functional relevance of EVs. In parallel, we analysed the secretome from the same cells and found a distinctly different set of 48 differentially abundant proteins related to extracellular matrix organisation and remodelling, growth factor response, RNA metabolism and the proteasome. The EVs and secretome sets of proteins only shared two identifiers indicating that the sorting of proteins towards EVs or the secretory pathway is tightly regulated for different functions. ., This work was funded by Plan Nacional de I + D + I and Instituto de Salud Carlos III (ISCIII), Subdirección General de Evaluación y Fomento de la Investigación Sanitaria (PI16/00579, PI19/00122) and Fundación Noelia. Spanish Ministry of Science, Innovation and Universities (PID2019-110356RB-I00/AEI/10.13039/501100011033).




Growth Differentiation Factor 15 is a potential biomarker of therapeutic response for TK2 deficient myopathy

Dipòsit Digital de Documents de la UAB
  • Domínguez-González, C|||0000-0001-5151-988X
  • Badosa, Carmen
  • Madruga-Garrido, Marcos
  • Martí, Itxaso|||0000-0003-0578-9568
  • Paradas, Carmen|||0000-0002-6917-2236
  • Ortez González, Carlos Ignacio|||0000-0001-8187-8103
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
  • Berardo, Andres
  • Alonso-Pérez, Jorge|||0000-0001-8866-5186
  • Trifunov, Selena|||0000-0002-1807-9621
  • Cuadras, Daniel|||0000-0001-8780-1764
  • Kalko, Susana G.|||0000-0002-6701-0233
  • Blázquez-Bermejo, Cora
  • Cámara, Yolanda|||0000-0003-2458-6942
  • Martí, Ramon A.|||0000-0002-8273-9540
  • Mavillard, Fabiola|||0000-0002-1460-0483
  • Martin, Miguel A.
  • Montoya, Julio|||0000-0003-1770-6299
  • Ruiz-Pesini, Eduardo|||0000-0002-0269-7337
  • Villarroya, Joan|||0000-0002-7859-1109
  • Montero, Raquel|||0000-0003-0609-5701
  • Villarroya, Francesc|||0000-0003-1266-9142
  • Artuch, R.|||0000-0002-3422-9685
  • Hirano, Michio|||0000-0002-7070-7402
  • Nascimento, Andrés
  • Jiménez Mallebrera, Cecilia|||0000-0001-8203-7103
GDF-15 is a biomarker for mitochondrial diseases. We investigated the application of GDF-15 as biomarker of disease severity and response to deoxynucleoside treatment in patients with thymidine kinase 2 (TK2) deficiency and compared it to FGF-21. GDF-15 and FGF-21 were measured in serum from 24 patients with TK2 deficiency treated 1-49 months with oral deoxynucleosides. Patients were grouped according to age at treatment and biomarkers were analyzed at baseline and various time points after treatment initiation. GDF-15 was elevated on average 30-fold in children and 6-fold in adults before the start of treatment. There was a significant correlation between basal GDF-15 and severity based on pretreatment distance walked (6MWT) and weight (BMI). During treatment, GDF-15 significantly declined, and the decrease was accompanied by relevant clinical improvements. The decline was greater in the paediatric group, which included the most severe patients and showed the greatest clinical benefit, than in the adult patients. The decline of FGF-21 was less prominent and consistent. GDF-15 is a potential biomarker of severity and of therapeutic response for patients with TK2 deficiency. In addition, we show evidence of clinical benefit of deoxynucleoside treatment, especially when treatment is initiated at an early age.




Late-onset thymidine kinase 2 deficiency, a review of 18 cases

Dipòsit Digital de Documents de la UAB
  • Domínguez-González, C|||0000-0001-5151-988X
  • Hernández-Laín, Aurelio
  • Rivas, Eloy
  • Hernández Voth, Ana
  • Sayas Catalán, Javier
  • Fernández-Torrón, Roberto
  • Fuiza-Luces, Carmen
  • García García, Jorge
  • Morís, Germán|||0000-0001-7608-2194
  • Olive, Montse|||0000-0001-5727-0165
  • Miralles, Frances
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
  • Caballero Sahelices, Concesa
  • Méndez-Ferrer, Bosco
  • Martí, Ramon A.|||0000-0002-8273-9540
  • Garcia-Arumi, Elena|||0000-0003-1848-005X
  • Badosa, María Carmen
  • Esteban, Jesús
  • Jiménez Mallebrera, Cecilia|||0000-0001-8203-7103
  • Encinar, Alberto Blazquez
  • Arenas, Joaquín|||0000-0002-2877-5049
  • Hirano, Michio|||0000-0002-7070-7402
  • Martin, Miguel Ángel
  • Paradas, Carmen|||0000-0002-6917-2236
TK2 gene encodes for mitochondrial thymidine kinase, which phosphorylates the pyrimidine nucleosides thymidine and deoxycytidine. Recessive mutations in the TK2 gene are responsible for the 'myopathic form' of the mitochondrial depletion/multiple deletions syndrome, with a wide spectrum of severity. We describe 18 patients with mitochondrial myopathy due to mutations in the TK2 gene with absence of clinical symptoms until the age of 12. The mean age of onset was 31 years. The first symptom was muscle limb weakness in 10/18, eyelid ptosis in 6/18, and respiratory insufficiency in 2/18. All patients developed variable muscle weakness during the evolution of the disease. Half of patients presented difficulty in swallowing. All patients showed evidence of respiratory muscle weakness, with need for non-invasive Mechanical Ventilation in 12/18. Four patients had deceased, all of them due to respiratory insufficiency. We identified common radiological features in muscle magnetic resonance, where the most severely affected muscles were the gluteus maximus, semitendinosus and sartorius. On muscle biopsies typical signs of mitochondrial dysfunction were associated with dystrophic changes. All mutations identified were previously reported, being the most frequent the in-frame deletion p.Lys202del. All cases showed multiple mtDNA deletions but mtDNA depletion was present only in two patients. The late-onset is the less frequent form of presentation of the TK2 deficiency and its natural history is not well known. Patients with late onset TK2 deficiency have a consistent and recognizable clinical phenotype and a poor prognosis, due to the high risk of early and progressive respiratory insufficiency.